anti-P. gingivalis cysteine protease mAb

This monoclonal antibody (IgG1 Kappa) targets a novel epitope of the cysteine protease (gingipain) produced by the periodontal pathogen *Porphyromonas gingivalis*. Developed by researchers at China Medical University in Taiwan, the antibody is intended for the treatment of rheumatoid arthritis (RA), based on the link between *P. gingivalis* infection and the induction of citrullinated proteins that trigger RA. In preclinical studies using a collagen-induced arthritis (CIA) rat model, the mAb demonstrated significant therapeutic efficacy, including dose-dependent reductions in joint inflammation, synovial proliferation, and cartilage damage. The antibody exhibits high binding affinity to FCγRIIb and FCγRIII and is characterized by high thermal stability.

Other names

monoclonal antibody against the novel epitope of cysteine protease from P. gingivalis